Cell Biology, Cancer Research, Biomaterials, Transplantation
108
Scopus Publications
Scopus Publications
Modeling hepatocellular carcinoma and its microenvironment on a chip Orsola Mocellin, Stéphane Treillard, Abbie Robinson, Aleksandra Olczyk, Thomas Olivier, Chee P. Ng, Arthur Stok, Gilles van Tienderen, Monique M. A. Verstegen, Jeroen Heijmans, Dorota Kurek, Sebastian J. Trietsch, Henriëtte L. Lanz, Paul Vulto, Jos Joore, Karla Queiroz Cell Death Discovery, 2026 Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Its incidence is increasing and is closely related to advanced liver disease. Interactions in the HCC microenvironment between tumor cells and the associated stroma actively regulate tumor initiation, progression, metastasis, and therapy response. Effective drug development increasingly requires advanced models that can be utilized in the earliest stages of compound and target discovery. Here we report a phenotypic screen on an advanced HCC patient-derived chip (PDChip) model. The vascularized HCC PDChip models include relevant cellular players of the HCC microenvironment. We assessed the effect of 28 treatment conditions on a panel of 8 primary HCC tumors and 2 cell lines. Approximately 1200 HCC PDchips were grown under perfusion flow, exposed to treatments, and subsequently assessed for viability, tumor-associated vasculature responses and chemokine and cytokine changes. Although the SoC therapeutics sorafenib and lenvatinib reduced culture viability and produced profound changes in the organization of the vascular beds, they did not affect the tumor cell population in these cultures. Atorvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, reduced PDChips viability but did not affect vascular bed organization. Sorafenib, lenvatinib and atorvastatin also affected chemokine and cytokine release. Tocilizumab, galunisertib, and vactosertib decreased the level of IL6, a relevant prognostic marker for HCC, while IL6 was increased by halofuginone. In conclusion, HCC PDChip models enabled a detailed evaluation of drug-induced responses in the tumor and associated microenvironment, highlighting their importance in preclinical research for understanding diseases and developing new drugs.
Functional characterization of BAP1 mutations in genome edited cholangiocarcinoma organoids: Role in cell death and drug responses Wunan Mi, Shaojun Shi, Imre F. Schene, Indi P. Joore, Henk P. Roest, Sabine A. Fuchs, Luc J.W. van der Laan, Monique M.A. Verstegen Iscience, 2026 Cholangiocarcinoma (CCA) is a genetically heterogeneous malignancy of the bile ducts with limited effective treatments and variable chemotherapeutic responses. BRCA1-associated protein 1 (BAP1), a tumor suppressor gene frequently mutated in CCA, encodes a nuclear deubiquitinating enzyme involved in chromatin remodeling and cell death regulation. In this study, we investigated the role of BAP1 mutations in programmed cell death and drug response using patient-derived and prime-edited CCA organoids (CCAOs). BAP1-mutant organoids exhibited impaired activation of apoptosis and necroptosis, as evidenced by reduced cleaved caspase-3 and pMLKL expression. Transcriptomic analysis revealed BAP1-dependent gene expression changes including enrichment of pathways related to stress response, ion transport, and metabolic detoxification. Interesting, BAP1 mutant CCAOs showed enhanced sensitivity to sorafenib, a multikinase inhibitor commonly used in biliary tract cancer. These findings highlight BAP1 as a modulator of cell death and a potential predictive biomarker for sorafenib response in CCA, with implications for personalized therapy design.
Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery Jiajing Li, Xin Wang, Yibo Ding, Fang Qin, Shirlene T.S. de Lima, Lito Papamichail, Rick Schraauwen, Julia Forato, Ingra M. Claro, Xinyi Hua, Leda M. Simões Mello, Dewy Mae Offermans, Monique M.A. Verstegen, Marjan Boter, Maikel P. Peppelenbosch, Anna Barbiero, Elisabetta Pagani, Harry L.A. Janssen, José A. Telmos Silva, Magnun N.N. dos Santos, Eder C. Pincinato, José Luiz Proenca-Modena, Pengfei Li, Adam A. Anas, Luc J.W. van der Laan, Concetta Castilletti, Bas B. Oude Munnink, William M. de Souza, Wenshi Wang, Qiuwei Pan Cell Reports Medicine, 2026 Oropouche virus (OROV) is a neglected, re-emerging arbovirus that typically causes self-limiting febrile illness but can also lead to severe complications. With no approved vaccines or treatments available, we integrate clinical data with human liver-derived organoids to assess liver involvement in OROV infection and identify antiviral candidates through drug repurposing. Patient blood tests show elevated liver enzymes, indicating OROV-associated hepatic dysfunction. OROV isolates productively infect liver organoids and induce severe cellular damage. Transcriptomic profiling reveals strong virus-host interactions, including activation of interferon-stimulated genes and cell death pathways. Pharmacological inhibition of the interferon pathway enhances OROV replication, whereas treatment with therapeutic interferon-α suppresses the infection. Molnupiravir, a clinically approved antiviral drug targeting viral RNA-dependent RNA polymerase, markedly inhibits OROV replication and mitigates virus-induced cytopathology. Combining molnupiravir with interferon-α results in synergistic antiviral activity, indicating the complementarity of virus-targeted and host-directed strategies. These findings strengthen preparedness and response to OROV emergence.
Beyond Decellularization: Remnant Mitochondrial DNA Can Act as Hidden Damage-Associated Molecular Pattern Elena V. A. van Hengel, Kuan Liu, Henk P. Roest, Jorke Willemse, Kimberley Ober-Vliegen, Selina M. W. Teurlings, Jeroen de Jonge, Monique M. A. Verstegen, Luc J. W. van der Laan Bioengineering, 2026 Tissue decellularization aims to obtain bioscaffolds for regenerative applications by removing all cellular components while preserving the extracellular matrix (ECM) architecture. Although decellularization removes the majority of linear nuclear DNA (nDNA), residual amounts remain detectable. However, the fate of circular mitochondrial DNA (mtDNA) after decellularization has not yet been reported. Cell death or injury can cause the release of mtDNA, which is resistant to breakdown by exonucleases. Extracellular mtDNA acts as a damage-associated molecular pattern (DAMP) that can trigger immune responses. The aim of this study is to assess the presence of residual mtDNA in the liver, bile duct, and vascular scaffolds after decellularization and whether this causes inflammatory responses in macrophages. Decellularized tissues showed a marked reduction in total DNA content well below the threshold of 50 ng/mg tissue. However, in liver and vascular scaffolds, a relative increase in the mtDNA:nDNA ratio was detected in the remnant DNA fraction. Residual mtDNA in bioscaffolds acted as DAMPs causing macrophage activation, as shown by increased cell proliferation and cytokine production. Strategies to further reduce remnant mtDNA were tested. We found that treatment with the endonuclease enzyme HpaII was effective in degrading residual mtDNA. Importantly, mtDNA removal resulted in a significantly reduced macrophage activation. In conclusion, our study shows that mtDNA is relatively resistant to the decellularization procedure and can act as a DAMP in bioscaffolds. This underscores the importance of removing mtDNA from decellularized bioscaffolds to improve the immunocompatibility for biomedical applications.
Cholangiocarcinoma 2026: status quo, unmet needs and priorities Jesus M. Banales, Pedro M. Rodrigues, Silvia Affò, Jesper B. Andersen, Patricia Aspichueta, Luke Boulter, John Bridgewater, Diego F. Calvisi, Andres Cardenas, Vincenzo Cardinale, Guido Carpino, Cédric Coulouarn, Cristina Dopazo, Julien Edeline, Luca Fabris, Trine Folseraas, Alejandro Forner, Benjamin Goeppert, Mathias Heikenwalder, Timothy J. Kendall, Shahid A. Khan, Heinz-Josef Klümpen, Bas Groot Koerkamp, Angela Lamarca, Stacie Lindsey, Ana Lleo, Tom Luedde, Rocio I. R. Macias, Helen Morement, Jean-Charles Nault, Paula Olaizola, Maria J. Perugorria, Chiara Raggi, Lorenza Rimassa, Anna Saborowski, Juan W. Valle, Mathew Vithayathil, Arndt Vogel, Chiara Braconi, , Abel Sanchez, Adelaida La Casta, Aldo J. Montano-Loza, Alessandra Elvevi, Alessandro Parisi, Alexander Link, Ana Landa-Magdalena, Andres Munoz, Anthony Turpin, Anu Ustav, Apinya Jusakul, Arun Valsan, Benjamin Dwyer, Bogdan S. Ungureanu, Bruno Sangro, Christoph Schramm, Cindy Neuzillet, Constantino Fondevila, David J. Pinato, David Malka, Domingo Balderramo, Elide Gutierrez, Elisa Lozano, Emmanuel Boleslawski, Enrique Carrera Estupinan, Ernesto Sparrelid, Eugenio Gaudio, Fatima Higuera De La Tijera, Flavio Rocha, Florence Troisfontaine, Francesca Ratti, Frank Lammert, Gianpaolo Vidili, Gonzalo Sapisochin, Gregory B. Lesinski, Gregory Gores, Hannes Jansson, Hassan Malik, Jan Philipp Jonas, Javier Diaz Ferrer, Javier Vaquero, Jens U. Marquardt, Joana Espírito Santo, Jorge Adeva, Joris Erdmann, Jose J. G. Marin, Juan Carlos Roa, Juli Busquets, Juozas Kupcinskas, Krzysztof Zieniewicz, Lara Heij, Laura Goff, Laura Izquierdo-Sanchez, Leonardo G. Da Fonseca, Luca Maroni, Luis Bujanda, Mairéad G. McNamara, Marco Carbone, Marco Marzioni, Marco Rengo, Maria Melanie Deutsch, Mariano Ponz, Mario Strazzabosco, Markus Peck-Radosavljevic, Massimiliano Cadamuro, Massimiliano Salati, Massimo Colombo, Matei Mandea, Matias A. Avila, Matthias Evert, Mina Komuta, Mitesh Borad, Mohamed Bouattour, Mohamed El-Kassas, Monica I. Meneses-Medina, Monica Niger, Monique Verstegen, Nabeel Bardeesy, Nilofer Azad, Olivier Detry, Olivier Scatton, P. Martin Padilla-Machaca, Pilar Acedo, Pim B. Olthof, Piotr Milkiewicz, Rachel Guest, Rachna Shroff, Robert Montal, Robin Kate Kelley, Ruidong Xue, Sergio Gradilone, Shishir K. Maithel, Silvestre Vicent, Siwanon Jirawatnotai, Stefano Caruso, Stephanie Roessler, Stephen L. Chan, Stephen P. Pereira, Teresa Macarulla, Thomas Gruenberger, Tian V. Tian, Tim F. Greten, Tudor Mocan, Tushar Patel, Umair Mahmood, Umberto Cillo, Vera Megdanova, Victor Lopez-Lopez Nature Reviews Gastroenterology and Hepatology, 2026
Removal of Porcine Endogenous Retroviruses in Decellularized Liver Bioscaffolds Elena V. A. van Hengel, Dubravka Drabek, Henk. P. Roest, Jorke Willemse, Lieve J. Reniers, Hera Stallmann, Jeroen de Jonge, Frank G. Grosveld, Luc J. W. van der Laan, Monique M. A. Verstegen Xenotransplantation, 2025 Tissue engineering using decellularized liver scaffolds presents a promising approach in regenerative medicine, offering a potential alternative to donor organ transplantation. The use of human livers as a bioscaffold is restricted by their limited availability and quality. Porcine livers offer an alternative due to their anatomical and physiological similarities to human livers. However, applying porcine‐derived biomaterials in a clinical setting poses a risk of pathogen transmission, which is a noteworthy concern. Porcine endogenous retroviruses (PERVs), which are integrated into the genome of all pig breeds, are of particular concern, as subclasses PERV‐A and PERV‐B have shown to infect human cells in vitro. It is therefore essential to effectively remove all PERVs when manufacturing porcine scaffolds. In this study, we assessed the presence of PERV‐specific DNA, RNA, and protein in decellularized porcine livers. Our findings prove that genetic and protein PERV material was effectively removed from porcine livers during our decellularization procedure. This finding substantiates the potential of using decellularized scaffolds of porcine origin for clinical applications without risk of PERV transmission.
Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases and enable development of multitarget therapeutics Kuan Liu, Yining Wang, Jiajing Li, Jiahua Zhou, Ana Maria Gonçalves da Silva, Clara Suñer, Zhe Dai, Rick Schraauwen, Patrick P. C. Boor, Kimberley Ober-Vliegen, Francijna van den Hil, Dewy M. Offermans, Theano Tsikari, Ibrahim Ayada, Maikel P. Peppelenbosch, Martin E. van Royen, Monique M. A. Verstegen, Yijin Wang, Chloe M. Orkin, Harry L. A. Janssen, Valeria V. Orlova, Pengfei Li, Oriol Mitjà, Amaro Nunes Duarte-Neto, Luc J. W. van der Laan, Qiuwei Pan Nature Biomedical Engineering, 2025
Apoptosis regulators of the Bcl-2 family play a key role in chemoresistance of cholangiocarcinoma organoids Wunan Mi, Gilles S. van Tienderen, Shaojun Shi, Amy Broeders, Kathryn Monfils, Henk P. Roest, Luc J. W. van der Laan, Monique M. A. Verstegen International Journal of Cancer, 2025 Cholangiocarcinoma (CCA) is a rare but devastating liver cancer which is commonly diagnosed at a late stage and often resistant to chemotherapy. Bcl‐2 family members, which control apoptotic cell death, are known to be involved in the chemoresistance of some cancer types. This study investigated the role of Bcl‐2 family members in the chemoresistance of cholangiocarcinoma organoids (CCAOs) in both undifferentiated and matured branching phenotypes (BRCCAOs). Patient‐derived CCAOs and BRCCAOs were cultured to assess chemoresistance to an FDA‐approved anticancer drug panel by testing cell viability using ATP quantification and apoptotic cell death by cleaved caspase 3 staining. More specifically, sensitivity to the first‐line drug gemcitabine was tested in combination with Bcl‐2 family inhibitors or activators. We found that in gemcitabine‐resistant CCAOs, inhibition of Bcl‐xl could overcome gemcitabine resistance and induce apoptotic cell death. Although inhibition of Mcl‐1 or activation of Bax induced spontaneous cell death, this could not overcome gemcitabine resistance. The BRCCAOs, which mimic tumor architecture better than CCAOs, show broader chemoresistance to anticancer drugs. Of note, in the resistant BRCCAOs, Bcl‐xl inhibition could restore gemcitabine sensitivity. In conclusion, this study shows that targeting Bcl‐xl can overcome chemoresistance to gemcitabine in CCA organoids. CCAOs and BRCCAOs provide good preclinical models for testing new drug combinations and assessing personalized therapeutic approaches.
Optimizing the Infusion Route of Human Bone Marrow Mesenchymal Stromal Cells to Mitigate Liver Ischemia–Reperfusion Injury in a Porcine Model Stefan H. Luijmes, Job P. van Kooten, Henk P. Roest, Jubi de Haan, Michail Doukas, Cornelia J. Verhoeven, Kairong Wang, Jorke Willemse, Luc J. W. van der Laan, Monique M. A. Verstegen, Jeroen de Jonge Cells, 2025 Mesenchymal stromal cells (MSC) have been shown to mitigate IRI through their anti-inflammatory and immune-modulating capacities. This study aims to demonstrate the feasibility, safety, and effectiveness of hepatic administration of bone marrow-derived (BM)-MSCs in a large pig model relevant to human anatomy. After complete vascular exclusion for 45 min, 3 × 106 human BM-MSCs/kg body weight were infused via the portal vein or hepatic artery. BM-MSC infusion did not cause obstruction of hepatic or pulmonary blood flow within 6 h after infusion. Cells were effectively retained in the liver, being undetectable in peripheral blood, lung, and spleen samples. Human B2M expression, as a marker for BM-MSC presence, was significantly higher for the left liver lobe in arterial infusion compared to portal infusion. In liver samples with high BM-MSC levels, we identified the prevention of up- or downregulation of some genes related to inflammation and energy metabolism that was present in non-treated control samples, indicating biological effects within 6 h of infusion. We conclude that hepatic BM-MSC infusion is feasible and safe, with the hepatic artery serving as the optimal administration route for homogenous distribution. These findings pave the way for clinical studies on MSC infusion in IRI, either in situ in liver conditions or ex situ during machine perfusion.
Clinical applications of human organoids Monique M. A. Verstegen, Rob P. Coppes, Anne Beghin, Paolo De Coppi, Mattia F. M. Gerli, Nienke de Graeff, Qiuwei Pan, Yoshimasa Saito, Shaojun Shi, Amir A. Zadpoor, Luc J. W. van der Laan Nature Medicine, 2025
Accelerated production of human epithelial organoids in a miniaturized spinning bioreactor Shicheng Ye, Ary Marsee, Gilles S. van Tienderen, Mohammad Rezaeimoghaddam, Hafsah Sheikh, Roos-Anne Samsom, Eelco J.P. de Koning, Sabine Fuchs, Monique M.A. Verstegen, Luc J.W. van der Laan, Frans van de Vosse, Jos Malda, Keita Ito, Bart Spee, Kerstin Schneeberger Cell Reports Methods, 2024
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance Diego F. Calvisi, Luke Boulter, Javier Vaquero, Anna Saborowski, Luca Fabris, Pedro M. Rodrigues, Cédric Coulouarn, Rui E. Castro, Oreste Segatto, Chiara Raggi, Luc J. W. van der Laan, Guido Carpino, Benjamin Goeppert, Stephanie Roessler, Timothy J. Kendall, Matthias Evert, Ester Gonzalez-Sanchez, Juan W. Valle, Arndt Vogel, John Bridgewater, Mitesh J. Borad, Gregory J. Gores, Lewis R. Roberts, Jose J. G. Marin, Jesper B. Andersen, Domenico Alvaro, Alejandro Forner, Jesus M. Banales, Vincenzo Cardinale, Rocio I. R. Macias, Silve Vicent, Xin Chen, Chiara Braconi, Monique M. A. Verstegen, Laura Fouassier, Lewis Roberts, Alexander Scheiter, Florin M. Selaru, Katja Evert, Kirsten Utpatel, Laura Broutier, Massimiliano Cadamuro, Meritxell Huch, Robert Goldin, Sergio A. Gradilone, Yoshimasa Saito, and Nature Reviews Gastroenterology and Hepatology, 2023
Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells Guoying Zhou, Ruby Lieshout, Gilles S. van Tienderen, Valeska de Ruiter, Martin E. van Royen, Patrick P. C. Boor, Luc Magré, Jyaysi Desai, Kübra Köten, Yik Yang Kan, Zhouhong Ge, Lucia Campos Carrascosa, Cecile Geuijen, Dave Sprengers, Luc J. W. van der Laan, Monique M. A. Verstegen, Jaap Kwekkeboom British Journal of Cancer, 2022
Human branching cholangiocyte organoids recapitulate functional bile duct formation Floris J.M. Roos, Gilles S. van Tienderen, Haoyu Wu, Ignacio Bordeu, Dina Vinke, Laura Muñoz Albarinos, Kathryn Monfils, Sabrah Niesten, Ron Smits, Jorke Willemse, Oskar Rosmark, Gunilla Westergren-Thorsson, Daniel J. Kunz, Maurice de Wit, Pim J. French, Ludovic Vallier, Jan N.M. IJzermans, Richard Bartfai, Hendrik Marks, Ben D. Simons, Martin E. van Royen, Monique M.A. Verstegen, Luc J.W. van der Laan Cell Stem Cell, 2022
The potential and limitations of intrahepatic cholangiocyte organoids to study inborn errors of metabolism Vivian Lehmann, Imre F. Schene, Arif I. Ardisasmita, Nalan Liv, Tineke Veenendaal, Judith Klumperman, Hubert P. J. van der Doef, Henkjan J. Verkade, Monique M. A. Verstegen, Luc J. W. van der Laan, Judith J. M. Jans, Nanda M. Verhoeven‐Duif, Peter M. van Hasselt, Edward E. S. Nieuwenhuis, Bart Spee, Sabine A. Fuchs Journal of Inherited Metabolic Disease, 2022
Precancerous liver diseases do not cause increased mutagenesis in liver stem cells Luan Nguyen, Myrthe Jager, Ruby Lieshout, Petra E. de Ruiter, Mauro D. Locati, Nicolle Besselink, Bastiaan van der Roest, Roel Janssen, Sander Boymans, Jeroen de Jonge, Jan N. M. IJzermans, Michail Doukas, Monique M. A. Verstegen, Ruben van Boxtel, Luc J. W. van der Laan, Edwin Cuppen, Ewart Kuijk Communications Biology, 2021
Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma Elisa De Crignis, Tanvir Hossain, Shahla Romal, Fabrizia Carofiglio, Panagiotis Moulos, Mir Mubashir Khalid, Shringar Rao, Ameneh Bazrafshan, Monique MA Verstegen, Farzin Pourfarzad, Christina Koutsothanassis, Helmuth Gehart, Tsung Wai Kan, Robert-Jan Palstra, Charles Boucher, Jan NM IJzermans, Meritxell Huch, Sylvia F Boj, Robert Vries, Hans Clevers, Luc JW van der Laan, Pantelis Hatzis, Tokameh Mahmoudi Elife, 2021
Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids Ary Marsee, Floris J.M. Roos, Monique M.A. Verstegen, Ary Marsee, Floris Roos, Monique Verstegen, Hans Clevers, Ludovic Vallier, Takanori Takebe, Meritxell Huch, Weng Chuan Peng, Stuart Forbes, Frédéric Lemaigre, Eelco de Koning, Helmuth Gehart, Luc van der Laan, Bart Spee, Sylvia Boj, Pedro Baptista, Kerstin Schneeberger, Carol Soroka, Markus Heim, Sandro Nuciforo, Kenneth Zaret, Yoshimasa Saito, Matthias Lutolf, Vincenzo Cardinale, Ben Simons, Sven van IJzendoorn, Akihide Kamiya, Hiromi Chikada, Shuyong Wang, Seon Ju Mun, Myung Jin Son, Tamer Tevfik Onder, James Boyer, Toshiro Sato, Nikitas Georgakopoulos, Andre Meneses, Laura Broutier, Luke Boulter, Dominic Grün, Jan IJzermans, Benedetta Artegiani, Ruben van Boxtel, Ewart Kuijk, Guido Carpino, Gary Peltz, Jesus Banales, Nancy Man, Luigi Aloia, Nicholas LaRusso, Gregory George, Casey Rimland, George Yeoh, Anne Grappin-Botton, Daniel Stange, Nicole Prior, Janina E.E. Tirnitz-Parker, Emma Andersson, Chiara Braconi, Nicholas Hannan, Wei-Yu Lu, Stephen Strom, Pau Sancho-Bru, Shinichiro Ogawa, Vincenzo Corbo, Madeline Lancaster, Huili Hu, Sabine Fuchs, Delilah Hendriks, Helmuth Gehart, Eelco de Koning, Frédéric Lemaigre, Stuart J. Forbes, Weng Chuan Peng, Meritxell Huch, Takanori Takebe, Ludovic Vallier, Hans Clevers, Luc J.W. van der Laan, Bart Spee Cell Stem Cell, 2021
The biological process of lysine-tRNA charging is therapeutically targetable in liver cancer Ruyi Zhang, Lisanne Noordam, Xumin Ou, Buyun Ma, Yunlong Li, Pronay Das, Shaojun Shi, Jiaye Liu, Ling Wang, Pengfei Li, Monique M. A. Verstegen, D. Srinivasa Reddy, Luc J. W. van der Laan, Maikel P. Peppelenbosch, Jaap Kwekkeboom, Ron Smits, Qiuwei Pan Liver International, 2021
Prime editing for functional repair in patient-derived disease models Imre F. Schene, Indi P. Joore, Rurika Oka, Michal Mokry, Anke H. M. van Vugt, Ruben van Boxtel, Hubert P. J. van der Doef, Luc J. W. van der Laan, Monique M. A. Verstegen, Peter M. van Hasselt, Edward E. S. Nieuwenhuis, Sabine A. Fuchs Nature Communications, 2020
LGR5 marks targetable tumor-initiating cells in mouse liver cancer Wanlu Cao, Meng Li, Jiaye Liu, Shaoshi Zhang, Lisanne Noordam, Monique M. A. Verstegen, Ling Wang, Buyun Ma, Shan Li, Wenshi Wang, Michiel Bolkestein, Michael Doukas, Kan Chen, Zhongren Ma, Marco Bruno, Dave Sprengers, Jaap Kwekkeboom, Luc J. W. van der Laan, Ron Smits, Maikel P. Peppelenbosch, Qiuwei Pan Nature Communications, 2020
Human extrahepatic and intrahepatic cholangiocyte organoids show region-specific differentiation potential and model cystic fibrosis-related bile duct disease Monique M. A. Verstegen, Floris J. M. Roos, Ksenia Burka, Helmuth Gehart, Myrthe Jager, Maaike de Wolf, Marcel J. C. Bijvelds, Hugo R. de Jonge, Arif I. Ardisasmita, Nick A. van Huizen, Henk P. Roest, Jeroen de Jonge, Michael Koch, Francesco Pampaloni, Sabine A. Fuchs, Imre F. Schene, Theo M. Luider, Hubert P. J. van der Doef, Frank A. J. A. Bodewes, Ruben H. J. de Kleine, Bart Spee, Gert-Jan Kremers, Hans Clevers, Jan N. M. IJzermans, Edwin Cuppen, Luc J. W. van der Laan Scientific Reports, 2020
Large-Scale Production of LGR5-Positive Bipotential Human Liver Stem Cells Kerstin Schneeberger, Natalia Sánchez‐Romero, Shicheng Ye, Frank G. van Steenbeek, Loes A. Oosterhoff, Iris Pla Palacin, Chen Chen, Monique E. van Wolferen, Gilles van Tienderen, Ruby Lieshout, Haaike Colemonts‐Vroninks, Imre Schene, Ruurdtje Hoekstra, Monique M.A. Verstegen, Luc J.W. van der Laan, Louis C. Penning, Sabine A. Fuchs, Hans Clevers, Joery De Kock, Pedro M. Baptista, Bart Spee Hepatology, 2020
Dynamics of Proliferative and Quiescent Stem Cells in Liver Homeostasis and Injury Wanlu Cao, Kan Chen, Michiel Bolkestein, Yuebang Yin, Monique M.A. Verstegen, Marcel J.C. Bijvelds, Wenshi Wang, Nesrin Tuysuz, Derk ten Berge, Dave Sprengers, Herold J. Metselaar, Luc J.W. van der Laan, Jaap Kwekkeboom, Ron Smits, Maikel P. Peppelenbosch, Qiuwei Pan Gastroenterology, 2017
Long-Term Adult Feline Liver Organoid Cultures for Disease Modeling of Hepatic Steatosis Hedwig S. Kruitwagen, Loes A. Oosterhoff, Ingrid G.W.H. Vernooij, Ingrid M. Schrall, Monique E. van Wolferen, Farah Bannink, Camille Roesch, Lisa van Uden, Martijn R. Molenaar, J. Bernd Helms, Guy C.M. Grinwis, Monique M.A. Verstegen, Luc J.W. van der Laan, Meritxell Huch, Niels Geijsen, Robert G. Vries, Hans Clevers, Jan Rothuizen, Baukje A. Schotanus, Louis C. Penning, Bart Spee Stem Cell Reports, 2017
Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells Nesrin Tüysüz, Louis van Bloois, Stieneke van den Brink, Harry Begthel, Monique M. A. Verstegen, Luis J. Cruz, Lijian Hui, Luc J. W. van der Laan, Jeroen de Jonge, Robert Vries, Eric Braakman, Enrico Mastrobattista, Jan J. Cornelissen, Hans Clevers, Derk ten Berge Nature Communications, 2017
Human primary liver cancer-derived organoid cultures for disease modeling and drug screening Laura Broutier, Gianmarco Mastrogiovanni, Monique MA Verstegen, Hayley E Francies, Lena Morrill Gavarró, Charles R Bradshaw, George E Allen, Robert Arnes-Benito, Olga Sidorova, Marcia P Gaspersz, Nikitas Georgakopoulos, Bon-Kyoung Koo, Sabine Dietmann, Susan E Davies, Raaj K Praseedom, Ruby Lieshout, Jan N M IJzermans, Stephen J Wigmore, Kourosh Saeb-Parsy, Mathew J Garnett, Luc JW van der Laan, Meritxell Huch Nature Medicine, 2017
Tissue-specific mutation accumulation in human adult stem cells during life Francis Blokzijl, Joep de Ligt, Myrthe Jager, Valentina Sasselli, Sophie Roerink, Nobuo Sasaki, Meritxell Huch, Sander Boymans, Ewart Kuijk, Pjotr Prins, Isaac J. Nijman, Inigo Martincorena, Michal Mokry, Caroline L. Wiegerinck, Sabine Middendorp, Toshiro Sato, Gerald Schwank, Edward E. S. Nieuwenhuis, Monique M. A. Verstegen, Luc J. W. van der Laan, Jeroen de Jonge, Jan N. M. IJzermans, Robert G. Vries, Marc van de Wetering, Michael R. Stratton, Hans Clevers, Edwin Cuppen, Ruben van Boxtel Nature, 2016
Long-term culture of genome-stable bipotent stem cells from adult human liver Meritxell Huch, Helmuth Gehart, Ruben van Boxtel, Karien Hamer, Francis Blokzijl, Monique M.A. Verstegen, Ewa Ellis, Martien van Wenum, Sabine A. Fuchs, Joep de Ligt, Marc van de Wetering, Nobuo Sasaki, Susanne J. Boers, Hans Kemperman, Jeroen de Jonge, Jan N.M. Ijzermans, Edward E.S. Nieuwenhuis, Ruurdtje Hoekstra, Stephen Strom, Robert R.G. Vries, Luc J.W. van der Laan, Edwin Cuppen, Hans Clevers Cell, 2015
Gene therapies for hepatitis C virus Monique M. A. Verstegen, Qiuwei Pan, Luc J. W. van der Laan Advances in Experimental Medicine and Biology, 2015
No evidence for circulating mesenchymal stem cells in patients with organ injury Martin J. Hoogduijn, Monique M.A. Verstegen, Anja U. Engela, Sander S. Korevaar, Marieke Roemeling-van Rhijn, Ana Merino, Marcella Franquesa, Jeroen de Jonge, Jan N. Ijzermans, Willem Weimar, Michiel G.H. Betjes, Carla C. Baan, Luc J.W. van der Laan Stem Cells and Development, 2014
Mobilization of hepatic mesenchymal stem cells from human liver grafts Qiuwei Pan, Suomi M.G. Fouraschen, Fatima S. F. Aerts Kaya, Monique M. Verstegen, Mario Pescatori, Andrew P. Stubbs, Wilfred van IJcken, Antoine van der Sloot, Ron Smits, Jaap Kwekkeboom, Herold J. Metselaar, Geert Kazemier, Jeroen de Jonge, Hugo W. Tilanus, Gerard Wagemaker, Harry L.A. Janssen, Luc J.W. van der Laan Liver Transplantation, 2011
Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia Irene Homminga, Rob Pieters, Anton W. Langerak, Johan J. de Rooi, Andrew Stubbs, Monique Verstegen, Maartje Vuerhard, Jessica Buijs-Gladdines, Clarissa Kooi, Petra Klous, Pieter van Vlierberghe, Adolfo A. Ferrando, Jean Michel Cayuela, Brenda Verhaaf, H. Berna Beverloo, Martin Horstmann, Valerie de Haas, Anna-Sophia Wiekmeijer, Karin Pike-Overzet, Frank J.T. Staal, Wouter de Laat, Jean Soulier, Francois Sigaux, Jules P.P. Meijerink Cancer Cell, 2011
Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy Annette Deichmann, Martijn H Brugman, Cynthia C Bartholomae, Kerstin Schwarzwaelder, Monique MA Verstegen, Steven J Howe, Anne Arens, Marion G Ott, Dieter Hoelzer, Reinhard Seger, Manuel Grez, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo, Alain Fischer, Anna Paruzynski, Richard Gabriel, Hanno Glimm, Ulrich Abel, Claudia Cattoglio, Fulvio Mavilio, Barbara Cassani, Alessandro Aiuti, Cynthia E Dunbar, Christopher Baum, H Bobby Gaspar, Adrian J Thrasher, Christof von Kalle, Manfred Schmidt, Gerard Wagemaker Molecular Therapy, 2011
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype Niek P. van Til, Merel Stok, Fatima S. F. Aerts Kaya, Monique C. de Waard, Elnaz Farahbakhshian, Trudi P. Visser, Marian A. Kroos, Edwin H. Jacobs, Monique A. Willart, Pascal van der Wegen, Bob J. Scholte, Bart N. Lambrecht, Dirk J. Duncker, Ans T. van der Ploeg, Arnold J. J. Reuser, Monique M. Verstegen, Gerard Wagemaker Blood, 2010
Gene therapy: Is IL2RG oncogenic in T-cell development? Karin Pike-Overzet, Dick de Ridder, Floor Weerkamp, Miranda R. M. Baert, Monique M. Verstegen, Martijn H. Brugman, Steven J. Howe, Marcel J. T. Reinders, Adrian J. Thrasher, Gerard Wagemaker, Jacques J. M. van Dongen, Frank J. T. Staal Nature, 2006
Hemopoëtische stamcellen (HSC) uit navelstrengbloed; bevorderen van uitgroei in SCID-muizen door middel van macrofagendepletie Tijdschrift Voor Kindergeneeskunde, 1996
